Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zydelig post-HSCT in B-cell malignancies
NCT03151057Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more comparing Idelalisib 100mg with Placebo (2 arms). Primary endpoint: Treatment-limiting Toxicities. Started Jul 2018; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03151057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151057.